Lavipharm S.A.

DB:BXA0 Stock Report

Market Cap: €265.1m

Lavipharm Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Telemaque Lavidas

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO

Telemaque Lavidas

2.3yrs
Tenure

Mr. Telemaque Jean Lavidas is Director of Center For Community Alternatives, Inc. Telemaque Lavidas serves as the President of Lavipharm Group International, a diversified healthcare group of companies act...

Leadership Team

NamePositionTenureCompensationOwnership
Telemaque Lavidas
CEO & Executive Board Member2.3yrsno datano data
Vassilis Baloumis
Group CFO & Investor Relations Officer4.4yrsno datano data
Panagiotis Kousoulis
Chief Manufacturing & Operations Officerno datano datano data
Evangelos Paterakis
Chief Accountantno datano datano data
Mariza Antonaki
Chief People & Technology Officer2.3yrsno datano data
Nikos Ladas
Chief Scientific Officer2.3yrsno datano data
Eleana Nikolopoulou
Director of Legal & Compliance and Corporate Secretary4.2yrsno datano data
Ilias Konstantopoulos
Director of Marketing & Sales CHCno datano datano data
Katerina Tsardaka
Director of Business Development & Acquisitions2.3yrsno datano data
Panagiotis Giannouleas
Deputy CEO & Director2.3yrsno datano data
Emmanouil Petrou
Head of Medical Affairs of Lavipharm Hellasno datano datano data
Ioannis Sarigiannidis
Chief Commercial Officer International2.3yrsno datano data
2.3yrs
Average Tenure

Experienced Management: BXA0's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Telemaque Lavidas
CEO & Executive Board Member6.9yrsno datano data
Panagiotis Giannouleas
Deputy CEO & Director2.3yrsno datano data
Venetsiana-Loukia Lavida
Vice Chairman of the Boardno datano datano data
Christos Diamandopoulos
Non Executive Directorno datano datano data
James Christopoulos
Independent Non Executive Directorno datano datano data
Vicky Kefalas
Independent Non-Executive Board Member3.3yrsno datano data
Sophia Kounenaki-Efraimoglou
Independent Chairperson of the Board6.5yrsno datano data
4.9yrs
Average Tenure

Experienced Board: BXA0's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 17:19
End of Day Share Price 2026/05/21 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.